Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06602063 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Surgery for Relapsed Ovarian Cancer in Precision

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Sep 2029 to Jun 2030v3 Show 6 more changesShow less
    • Start date: Jan 2025 to Jul 2025
    • Interventions: Sintilimab (Drug), surgery/chemotherapy (Procedure) to Iparomlimab/Tuvonralimab (Drug), surgery/chemotherapy (Procedure)
    • Eligibility criteria expanded, about 8 words
    • Study description shortened, about 29 words
    • Site contacts updated at 2 of 2 sites
    • Study title shortened, about 2 words
  2. Start date: Oct 2024 to Jan 2025v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This multicenter, biomarker-driven, patient-centric study aimed to evaluate the efficacy of secondary cytoreduction followed by platinum-based chemotherapy in combination with anti-PD1/CTLA-4 bispecifics therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC).
Trial Details
NCT Number NCT06602063
Lead Sponsor Shanghai Gynecologic Oncology Group
Collaborators: Shanghai Zhongshan Hospital, Tongji Hospital
Conditions
(from sponsor)		 Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Related terms Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov